Normal
ImmuPharma interviews and webcasts

Click on the links below for the latest interviews regarding ImmuPharma. Please allow a short time for download:

6 February 2017
'We have absolutely no side effect profile in Lupuzor at all' says ImmuPharma chairman
Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) spoke to Proactive to give an update on the company's progress with its phase-III clinical trial of Lupuzor, a treatment for Lupus - a life threatening auto-immune disease.

Proactive interview


27 January 2017
Tim McCarthy, Chairman of ImmuPharma talks to Vox Markets and gives update on their, phase III clinIcal trials for its lead drug Lupuzor.

Vox markets interview


26 January 2017
Immupharma Plc – A multi-billion dollar selling drug
Immupharma Plc (LON:IMM) Non-Executive Chairman Tim McCarthy talks to DirectorsTalk about its phase 3 trial of Lupuzor. Tim explains the importance of completing the recruitment of the 200 patients and stay on track, the significance of the 70 patients that are being dosed in the US, detail on the Lupuzor safety profile and its importance, the market potential of Lupuzor if approved and key milestones for ImmuPharma in 2017/2018.

Director's Talk interview


 

26 January 2017
Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update
Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk about the phase III trial update announced by Immupharma Plc (LON:IMM). Vadim talks us through the highlights and the keys points to take away from this update.

Director's Talk interview


8 September 2016
Tim McCarthy, Chairman of ImmuPharma talks to Proactive Investor, Vox Markets and Directors Talk on ImmuPharma being invited to open a new site in Mauritius, to enrol up to 30 Lupus patients. Click on the links below to see the interviews.

Proactive Investor interview

Director's Talk interview

Vox Markets interview


9 June 2016
Prof. Sylviane Muller speaks to Proactive Investor following the two day London Lupuzor Symposium presenting on Lupuzor’s unique mechanism of action and why it is so effective in treating Lupus patients, and how it can potentially be a treatment for other auto-immune diseases.

Click here to see video


4 May 2016
Tim McCarthy, ImmuPharma’s Chairman speaks to Proactive Investor following today’s Preliminary Results  announcement, giving progress on Lupuzor’s Phase III pivotal trial and the forthcoming Symposium on 8/9 June where the inventor of Lupuzor, Prof. Sylivane Muller will be in London presenting on Lupuzor’s unique mechanism of action and why it is so effective in treating Lupus patients, based on Phase IIb trials

Click here to see video


Tim McCarthy, Chairman of ImmuPharma, speaks to Proactive Investor following the announcement today that ImmuPharma has reached a significant milestone with first dosing in the US of Lupus patients for its pivotal Phase III Lupuzor trial

Click here to see video


ImmuPharma’s Chairman, Tim McCarthy, talks to Proactive Investor about the recent £8.3 million fundraising and progress on the Company’s lead drug, Lupuzor™ through its pivotal Phase III, trial.

Click here to see video


 
 
 
INVESTIGATORS MEETING, DECEMBER 2015, PARIS
LUPUZOR’S PIVOTAL PHASE III TRIAL
A summary video of the event including interviews with Prof Sylviane Muller, key ImmuPharma, Simbec-Orion and Principal Investigator personel.
 

ImmuPharma PLC Chairman Tim McCarthy Progress, Opportunity, Milestones
ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the recent progress with Lupuzor, opportunities for the company, milestones for 2016 and a re-rating for Immupharma shares?

 

Tim McCarthy, Chairman of ImmuPharma (LON:IMM), discusses the upcoming Phase III clinical trial of Lupuzor.
 

 

2015: Lupuzor founder Professor Sylviane Muller
Professor Sylviane Muller recently awarded Medal of Innovation from CNRS for work on both Lupuzor's mechanism of action and its applicability to other autoimmune conditions (some having orphan drug status). Click here for full announcement

  

Professor Sylviane Muller 
Click here for the video link 


For more interviews, in depth articles and up-to-minute analysis visit the Proactive Investors website. Click here